adult pulmonary Langerhans cell histiocytosis

Summary

adult pulmonary Langerhans cell histiocytosis (MONDO:0020520) is a disease and 1 clinical trial. A subtype of Langerhans cell histiocytosis specific to adulthood — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adult pulmonary Langerhans cell histiocytosis
Mondo ID	MONDO:0020520
Orphanet	99874
ICD-10-CM	J84.82
ICD-11	792398738
SNOMED CT	328611000119105
UMLS	C3161104
MedGen	853967
GARD	0025167
Is cancer (heuristic)	no

Disease family

This is a subtype of Langerhans cell histiocytosis specific to adulthood. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › interstitial lung disease specific to adulthood › Langerhans cell histiocytosis specific to adulthood › adult pulmonary Langerhans cell histiocytosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01225601	Not specified	COMPLETED	Prospective Evaluation of Adult Pulmonary Langerhans Cell Histiocytosis